Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Albert Lai

Showing results (191-200 of 209) with videos related to

Pageof 21
Sort By:
Journal of Neuro-Oncology|March 20, 2012
Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center studyWhitney B Pope, Xin Joe Qiao, Hyun J Kim, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|March 11, 2026
Integrating real-world data with gold-standard longitudinal clinical and genomic data to advance precision medicine for the Alzheimer's Disease Research Center Program and beyond: a proof-of-concept data platformSarah Biber, Jessica E Culhane, Maria G Prado, et al.
Journal of the National Cancer Institute|September 5, 2012
Identification of retinol binding protein 1 promoter hypermethylation in isocitrate dehydrogenase 1 and 2 mutant gliomasArthur P Chou, Reshmi Chowdhury, Sichen Li, et al.
Journal of Medicinal Chemistry|October 1, 2024
Discovery of Potent Azetidine-Benzoxazole MerTK Inhibitors with <i>In Vivo</i> Target EngagementRobin R Frey, Navendu Jana, Jacob V Gorman, et al.
Brain Pathology (Zurich, Switzerland)|February 27, 2013
PDGFRA amplification is common in pediatric and adult high-grade astrocytomas and identifies a poor prognostic group in IDH1 mutant glioblastomaJoanna J Phillips, Derick Aranda, David W Ellison, et al.
The Lancet. Oncology|November 28, 2021
Dabrafenib plus trametinib in patients with BRAF<sup>V600E</sup>-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trialPatrick Y Wen, Alexander Stein, Martin van den Bent, et al.
Science Translational Medicine|June 3, 2016
Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade gliomaTimothy F Cloughesy, Joseph Landolfi, Daniel J Hogan, et al.
Journal of Medicinal Chemistry|March 6, 2023
Discovery of a Potent Chloroacetamide GPX4 Inhibitor with Bioavailability to Enable Target Engagement in Mice, a Potential Tool Compound for Inducing Ferroptosis <i>In Vivo</i>John T Randolph, Matthew J O'Connor, Fei Han, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 26, 2011
Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of originAlbert Lai, Samir Kharbanda, Whitney B Pope, et al.
Neuro-Oncology|January 19, 2013
Combined analysis of O6-methylguanine-DNA methyltransferase protein expression and promoter methylation provides optimized prognostication of glioblastoma outcomeShadi Lalezari, Arthur P Chou, Anh Tran, et al.
Pageof 21

Showing results (191-200 of 209) with videos related to

Sort By:
Pageof 21
Journal of Neuro-Oncology|March 20, 2012
Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center studyWhitney B Pope, Xin Joe Qiao, Hyun J Kim, et al.
Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association|March 11, 2026
Integrating real-world data with gold-standard longitudinal clinical and genomic data to advance precision medicine for the Alzheimer's Disease Research Center Program and beyond: a proof-of-concept data platformSarah Biber, Jessica E Culhane, Maria G Prado, et al.
Journal of the National Cancer Institute|September 5, 2012
Identification of retinol binding protein 1 promoter hypermethylation in isocitrate dehydrogenase 1 and 2 mutant gliomasArthur P Chou, Reshmi Chowdhury, Sichen Li, et al.
Journal of Medicinal Chemistry|October 1, 2024
Discovery of Potent Azetidine-Benzoxazole MerTK Inhibitors with <i>In Vivo</i> Target EngagementRobin R Frey, Navendu Jana, Jacob V Gorman, et al.
Brain Pathology (Zurich, Switzerland)|February 27, 2013
PDGFRA amplification is common in pediatric and adult high-grade astrocytomas and identifies a poor prognostic group in IDH1 mutant glioblastomaJoanna J Phillips, Derick Aranda, David W Ellison, et al.
The Lancet. Oncology|November 28, 2021
Dabrafenib plus trametinib in patients with BRAF<sup>V600E</sup>-mutant low-grade and high-grade glioma (ROAR): a multicentre, open-label, single-arm, phase 2, basket trialPatrick Y Wen, Alexander Stein, Martin van den Bent, et al.
Science Translational Medicine|June 3, 2016
Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade gliomaTimothy F Cloughesy, Joseph Landolfi, Daniel J Hogan, et al.
Journal of Medicinal Chemistry|March 6, 2023
Discovery of a Potent Chloroacetamide GPX4 Inhibitor with Bioavailability to Enable Target Engagement in Mice, a Potential Tool Compound for Inducing Ferroptosis <i>In Vivo</i>John T Randolph, Matthew J O'Connor, Fei Han, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 26, 2011
Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of originAlbert Lai, Samir Kharbanda, Whitney B Pope, et al.
Neuro-Oncology|January 19, 2013
Combined analysis of O6-methylguanine-DNA methyltransferase protein expression and promoter methylation provides optimized prognostication of glioblastoma outcomeShadi Lalezari, Arthur P Chou, Anh Tran, et al.
Pageof 21